Download PDF
Thromb Haemost 1988; 59(02): 202-206
DOI: 10.1055/s-0038-1642754
Original Articles
Schattauer GmbH Stuttgart

Functional and Immunological Assays of F VIII in 133 Haemophiliacs - Characterization of a Subgroup of Patients with Mild Haemophilia A and Discrepancy in 1- and 2-Stage Assays

Armelle Parquet-Gernez
1   The Laboratoire d'Hemostase, Centre Regional de Transfusion Sanguine, Lille, France
,
Claudine Mazurier
1   The Laboratoire d'Hemostase, Centre Regional de Transfusion Sanguine, Lille, France
,
Maurice Goudemand
1   The Laboratoire d'Hemostase, Centre Regional de Transfusion Sanguine, Lille, France
› Author Affiliations
Further Information

Publication History

Received 09 June 1987

Accepted after revision25 November 1987

Publication Date:
21 May 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A systematic study of the levels of FVIII antigen and activity was done in 133 haemophiliacs. No measurable antigen was demonstrated in the 60 severe haemophiliacs, with the exception of 3 patients with levels ranging between 1.5 and 4.5 U/dl, which corresponded to a dramatic FVIII deficiency. The situation was more complex with the 73 moderate and mild haemophiliacs: 39 of them (53.4%) had a partial, concordant deficiency of both the antigen and the procoagulant activity (1- and 2-stage methods), likely corresponding to a decrease in the synthesis of normal FVIII. The conclusion for the other 34 patients, was a qualitative abnormality of FVIII, the levels of antigen in comparison with the procoagulant activity (1-stage method) appearing to be either very reduced (n = 6) or even nil (n = 8), or on the contrary very much higher (n = 20) or normal. For 11 patients in this last category, we found a clear discrepancy between the procoagulant activity levels obtained with the 2 different techniques, the 1-stage levels being higher than the 2-stage levels. This discrepancy which was stable with restudy on multiple occasions and found in different members of the same families was remedied when vWF was absent in one-stage assay. This suggests that we have identified a variant of haemophilia A with an inherited abnormality of FVIII characterized by an in vitro vWF-dependent expression of procoagulant activity.

Keywords

Haemophilia A - FVIII:Ag assay - FVIII:C assays
 

  • References

  • 1 Girma JP, Lavergne IM, Meyer D, Larrieu MJ. Immunoradiometric assay of factor VIII coagulant antigen using four human antibodies. Study of 27 cases of haemophilia A Br J Haematol 1981; 47: 269-282
    CrossrefPubMedGoogle Scholar
  • 2 Holmberg L, Borge L, Ljung R, Nilsson IM. Measurement of antihaemophilic factor antigen (VIII :CAg) with a solid phase immuno-radiometric method based on homologous non-haemophilic antibodies. Scand J Haematol 1979; 23: 17-27
    PubMedGoogle Scholar
  • 3 Hoyer LW. Biochemistry of factor VIII. Hemostasis and Thrombosis basic principles and clinical practice J. B. Lippincott Company Philadelphia Editor 1982; Chap, 4 44-45
    PubMedGoogle Scholar
  • 4 Lazarchik J, Hoyer LW. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-1052
    CrossrefPubMedGoogle Scholar
  • 5 Ljung R, Holmberg L, Nilsson IM. Inheritable molecular variants of moderate and mild hemophilia A. Acta Med Scand 1981; 209: 11-16
    PubMedGoogle Scholar
  • 6 Muller HP, van Tilburg NH, Bertina RM, Veltkamp JJ. Immunologic studies on the relationship between FVIII related antigen and FVIII procoagulant activity. Thromb Res 1980; 20: 85-96
    CrossrefPubMedGoogle Scholar
  • 7 Muller HP, van Tilburg NH, Bertina RM, Veltkamp JJ. Heterogeneity of haemophilia A: a study with three different antisera. Brit J Haematol 1982; 52: 485-94
    CrossrefPubMedGoogle Scholar
  • 8 Peake IR, Bloom AL, Giddings JC, Ludlam CA. An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand’s disease and fetal plasma and serum. Br J Haematol 1979; 42: 269-281
    CrossrefPubMedGoogle Scholar
  • 9 Reisner HM, Barrow ES, Graham JB. Radioimmunoassay for coagulant factor VIII related antigen (VIII:CAg). Thromb Res 1979; 14: 235-239
    CrossrefPubMedGoogle Scholar
  • 10 Reisner HM, Price WA, Blatt PM, Barrow ES, Graham JB. Factor VIII coagulant antigen in hemophilic plasma: a comparison of five alloantibodies. Blood 1980; 56: 615-619
    PubMedGoogle Scholar
  • 11 Rotblat F, Tuddenham EG D. Immunologic studies of factor VIII coagulant activity (VIII:C). Assays based on a haemophilic and on acquired antibody Thromb Res 1981; 21: 431-445
    CrossrefPubMedGoogle Scholar
  • 12 Stel HV, Veerman EC I, Huisman JG, Janssen MC, van Mourik JA. A rapid one-step immunoradiometric assay for factor VIII procoagulant antigen utilizing monoclonal antibodies. Thromb Haemostas 1983; 50: 860-863
    PubMedGoogle Scholar
  • 13 Brown JE, le Phuc Thuy, Carton CL, Hougie C. Studies on a monoclonal antibody to human factor VIII coagulant activity with a description of a facile two-site factor VIII coagulant antigen assay. J Lab Clin Med 1983; 101: 793-805
    PubMedGoogle Scholar
  • 14 Soulier JP, Larrieu MJ. Nouvelle methode de diagnostic de l’hemophilie. Dosage des facteurs antihemophiliques A et B Le Sang 1953; 24: 205
    PubMedGoogle Scholar
  • 15 Biggs R, Eveling J, Richards G. The assay of antihaemophilic globulin activity. Br J Haematol 1955; 1: 20
    CrossrefPubMedGoogle Scholar
  • 16 Austen DE G. The chromatography separation of factor VIII on aminohexyl sepharose. Br J Haematol 1979; 43: 669-674
    CrossrefPubMedGoogle Scholar
  • 17 Rosen S. Assay of factor VIILC with a chromogenic substrate. Scand J Haematol 1984; (Suppl. 33) Suppl 40: 139-145
    PubMedGoogle Scholar
  • 18 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 869-872
    PubMedGoogle Scholar
  • 19 Goudemand M, Foucaut M, Hutin A, Parquet-Gernez A. Les anticoagulants circulants anti-facteur VIII au cours de l’hemophilie A (Nature et mecanisme d’action). Nouv Rev Fr Hematol 1963; 3: 703-722
    PubMedGoogle Scholar
  • 20 Stel HV, Vanderkwast TH, Veerman EC I. Detection of factor VIII coagulant antigen in human liver tissue. Nature 1983; 303: 530-532
    CrossrefPubMedGoogle Scholar
  • 21 Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr 80.000 light chains. Eur J Biochem 1987; 166: 37-43
    CrossrefPubMedGoogle Scholar
  • 22 Rotblat A, Goodall D, O’Brien P, Rawlings E, Middleton S, Tuddenham EG D. Monoclonal antibodies to human procoagulant factor VIII. J Lab Clin Med 1983; 101: 736-746
    PubMedGoogle Scholar
  • 23 Parquet-Gernez A, Mazurier C, Goudemand M. Depistage des conductrices de Phemophilie A par dosage comparatif de Pactivite et de Pantigenicite facteur VIII. Path Biol 1974; (Suppl. 22) Suppl 37-42
    PubMedGoogle Scholar
  • 24 Weiss H, Hoyer L, Rickies I, Varna H, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content J Clin Invest 1973; 52: 2708
    CrossrefPubMedGoogle Scholar
  • 25 Kemball-Cook G, Barrowcliffe TW. Fractionation of human antibody to factor VIILC on IRMA for phospholipid binding sites on factor VIII:CAg. Br J Haematol 1984; 57: 633-636
    CrossrefPubMedGoogle Scholar
  • 26 Fulcher C A, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Nat Acad Sci USA 1985; 82: 7728-7732
    CrossrefPubMedGoogle Scholar
  • 27 Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-489
    PubMedGoogle Scholar
  • 28 Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vemar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330
    CrossrefPubMedGoogle Scholar
  • 29 Toole JJ, Knopf JL, Woznez JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
    CrossrefPubMedGoogle Scholar
  • 30 Hathaway WE, Christian MJ, Jacobson LJ. Variant mild hemophilia. Discrepancy in one-stage and two-stage factor VIII assays. Thromb Haemostas 1983; Suppl 50/1 Abs 1123
    PubMedGoogle Scholar
  • 31 Montgomery RM, Hathaway WE, Johnson J, Jacobson L, Muntean W. A variant of von Willebrand’s disease with abnormal expression of factor VIII procoagulant activity. Blood 1982; 60: 201-207
    PubMedGoogle Scholar
  • 32 Kobayashi I, Lamme S, Nilsson IM. The interaction between factor VIII clotting antigen and phospholipids in genetic variants of hemophilia and von Willebrand’s disease. Thromb Res 1984; 35: 65-75
    CrossrefPubMedGoogle Scholar
  • 33 Mertens K, van Wijngaarden A, Bertina RM. The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemostas 1985; 54: 654-660
    PubMedGoogle Scholar
  • 34 Mertens K, van Wijngaarden A, Bertina RM, Veltkamp JJ. The functional defect of factor VIII Leiden, a genetic variant of coagulant factor VIII. Thromb Haemostas 1985; 54: 650-653
    PubMedGoogle Scholar